Development of A MERS-CoV Replicon Cell Line for Antiviral Screening  

作　　者：Jing Chen Bing-Jie Hu Kai Zhao Yun Luo Hao-Feng Lin Zheng-Li Shi 

机构地区：[1]CAS Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,430071,China [2]University of Chinese Academy of Sciences,Beijing,100049,China

出　　处：《Virologica Sinica》2021年第4期730-735,共6页中国病毒学（英文版）

基　　金：This study was supported by the strategic priority research program of the Chinese academy of sciences(XDB29010101).

摘　　要：Middle East respiratory syndrome coronavirus(MERS-CoV)is the causative agent of a severe respiratory disease with a high mortality of~35%.The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening.In this study,we constructed a MERS-CoV replicon containing the Renilla luciferase(Rluc)reporter gene and a stable luciferase replicon-carrying cell line.Using this cell line,we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir,indicating that this cell line can be used to screen inhibitors of MERS-CoV replication.Importantly,the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling,providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.

关 键 词：Middle East respiratory syndrome coronavirus(MERS-CoV) Replicon cell line Antiviral screening Luciferase reporter gene 

分 类 号：R373[医药卫生—病原生物学]